Growth Metrics

Carlsmed (CARL) EBITDA Margin (2024 - 2026)

Carlsmed posted quarterly EBITDA Margin of 53.96% for Q1 2026, up 227.0% year-on-year from 16.5% in Q1 2025, and up 4.99% on a QoQ basis from 56.8% in Q4 2025.

Carlsmed (CARL) has 3 years of EBITDA Margin data on file, last reported at 53.96% in Q1 2026.

  • For the quarter ending Q1 2026, EBITDA Margin rose 227.0% year-over-year to 53.96%; the trailing twelve-month figure through Mar 2026 stood at 57.76% (up 1828.0% YoY), and the FY2025 full-year result was 58.67%, up 3063.0% from the prior year.
  • EBITDA Margin for Q1 2026 stood at 53.96%, up from 56.8% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 50.17% in Q4 2024 and bottomed at 118.56% in Q3 2024.
  • The 3-year median for EBITDA Margin is 56.51% (2025), against an average of 70.02%.
  • Peak annual rise in EBITDA Margin reached 5335 bps in 2025, while the deepest fall reached 663 bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 50.17% in 2024, then dropped by 13 bps to 56.8% in 2025, then grew by 5 bps to 53.96% in 2026.
  • The last three EBITDA Margin figures came in at 53.96% (Q1 2026), 56.8% (Q4 2025), and 65.21% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn 29.00%
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 3.36%
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 29.03%
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn 19.09%
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn 17.08%
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 27.87%
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -11.30%
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn 1.25%
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn 5.44%
10 Carlsmed 298.68 Mn 201.48 Mn 12.43 Mn -53.96%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -53.96%
Dec 31, 2025 -56.80%
Sep 30, 2025 -65.21%
Jun 30, 2025 -56.00%
Mar 31, 2025 -56.23%
Dec 31, 2024 -50.17%
Sep 30, 2024 -118.56%
Jun 30, 2024 -103.22%